Ophthotech Corp  

(Public, NASDAQ:OPHT)   Watch this stock  
Find more results for Kathy Wood�
-0.30 (-0.47%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 62.18 - 63.55
52 week 35.72 - 72.51
Open 63.28
Vol / Avg. 167,960.00/427,414.00
Mkt cap 2.21B
P/E     -
Div/yield     -
EPS -3.64
Shares 34.96M
Beta     -
Inst. own 98%
Feb 22, 2016
Q4 2015 Ophthotech Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 17, 2015
Ophthotech Corp at Stifel Healthcare Conference
Nov 17, 2015
Ophthotech Corp Conference Call To Discuss Ex-US Agreement Continues the Ownership of Sole US Rights for Fovista� -with Novartis
Nov 12, 2015
Ophthotech Corp at Ophthalmology Innovation Summit @ AAO
Nov 5, 2015
Q3 2015 Ophthotech Corp Earnings Release
Nov 5, 2015
Q3 2015 Ophthotech Corp Earnings Call
Sep 16, 2015
Ophthotech Corp at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1147.71% -283.02%
Operating margin -1375.96% -195.14%
EBITD margin - -194.83%
Return on average assets -34.44% -33.48%
Return on average equity -161.24% -78.30%
Employees 72 -
CDP Score - -


1 Penn Plz Fl 19
NEW YORK, NY 10119-0002
United States - Map
+1-212-8458200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ophthotech Corporation is a United States-based biopharmaceutical company. The Company is engaged in developing and commercializing therapies for the treatment of diseases of the eye and focuses on developing therapeutics for age-related macular degeneration (AMD). Its product pipeline includes Fovista anti-platelet derived growth factor (PDGF) therapy, which is in Phase III clinical trials for use in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. It prevents PDGF from binding to its natural receptor on pericytes, thus causing pericytes to be stripped from newly formed abnormal blood vessels.Its second product candidate, Zimura, an inhibitor of complement factor C5, is developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with anti-VEGF therapy and Fovista, for the treatment of wet AMD. Both Fovista and Zimura are aptamers, single strands of nucleic acid that binds with affinity to targets.

Officers and directors

David R. Guyer Chairman of the Board, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Samir C. Patel M.D. Vice Chairman of the Board, President
Age: 54
Bio & Compensation  - Reuters
Barbara Wood Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Henric Bjorn Bjarke Senior Vice President and Chief Commercial Officer
Bio & Compensation  - Reuters
Douglas K. Kollmorgen Senior Vice President - Quality Assurance
Bio & Compensation  - Reuters
Harvey N. Masonson M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Loni da Silva Senior Vice President - Global Regulatory Affairs
Bio & Compensation  - Reuters
Todd N. Smith Senior Vice President, Chief Commercial Officer
Age: 45
Bio & Compensation  - Reuters
David Shima Chief Scientific Officer
Bio & Compensation  - Reuters
Kathy Galante Vice President of Investor Relations and Corporate Communications
Bio & Compensation  - Reuters